Web Results

Gemtuzumab ozogamicin

en.wikipedia.org/wiki/Gemtuzumab_ozogamicin

Gemtuzumab ozogamicin is a drug-linked monoclonal antibody (an antibody- drug conjugate) that was used to treat acute myelogenous leukemia from 2000 to  ...

Gemtuzumab Ozogamicin - National Cancer Institute

www.cancer.gov/about-cancer/treatment/drugs/gemtuzumabozogamicin

This page contains brief information about gemtuzumab ozogamicin and a collection of links to more information about the use of this drug, research results, and ...

Press Announcements > FDA: Pfizer Voluntarily Withdraws Cancer ...

www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm216448.htm

Jun 21, 2010 ... Pfizer Inc. today announced the voluntary withdrawal from the U.S. market of the drug Mylotarg (gemtuzumab ozogamicin) for patients with ...

Gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth) ADC Review

adcreview.com/gemtuzumab-ozogamicin-mylotarg/

Jul 19, 2015 ... Gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) is a recombinant, humanized anti-CD33 monoclonal antibody (IgG4 κ ...

Gemtuzumab (Mylotarg®) - Cancer Information - Macmillan Cancer ...

www.macmillan.org.uk/cancerinformation/cancertreatment/treatmenttypes/biologicaltherapies/monoclonalantibodies/gemtuzumab.aspx

Information about the monoclonal antibody gemtuzumab (Mylotarg®), which is mainly used as part of research trials to treat some types of acute myeloid ...

Mylotarg - FDA prescribing information, side effects and uses

www.drugs.com/pro/mylotarg.html

Mylotarg® (gemtuzumab ozogamicin for Injection) is a chemotherapy agent composed of a recombinant humanized IgG4, kappa antibody conjugated with a  ...

Gemtuzumab Ozogamicin: Time to Resurrect?

jco.ascopubs.org/content/30/32/3921.full

Nov 10, 2012 ... On May 17, 2000, the US Food and Drug Administration (FDA) granted accelerated approval for the use of gemtuzumab ozogamicin (GO) in ...

Gemtuzumab ozogamicin in acute myeloid leukemia: a ... - NCBI

www.ncbi.nlm.nih.gov/pubmed/23591788

Blood. 2013 Jun 13;121(24):4838-41. doi: 10.1182/blood-2013-03-490482. Epub 2013 Apr 16. Gemtuzumab ozogamicin in acute myeloid leukemia: a ...

We Need Gemtuzumab Available Again to Treat AML - The ASCO Post

www.ascopost.com/issues/february-15-2013/we-need-gemtuzumab-available-again-to-treat-aml/

Feb 15, 2013 ... In an era of personalized and targeted therapy, it seems illogical to withdraw gemtuzumab, the only agent newly approved for the treatment of ...

Gemtuzumab ozogamicin: Indications, Side Effects, Warnings ...

www.drugs.com/cdi/gemtuzumab-ozogamicin.html

Easy to read patient leaflet for gemtuzumab ozogamicin. Includes indications, proper use, special instructions, precautions, and possible side effects.

More Info

Gemtuzumab Ozogamicin Voluntarily Withdrawn from U.S. Markets ...

www.cancer.gov

Jun 24, 2010 ... Pfizer, Inc., in agreement with the FDA, announced their discontinuing commercial marketing of gemtuzumab ozogamicin (Mylotarg) as of ...

Gemtuzumab ozogamicin in acute myeloid leukemia - Blood Journal

www.bloodjournal.org

Gemtuzumab ozogamicin (GO) consists of a humanized anti-CD33 monoclonal antibody conjugated with calicheamicin, a potent antitumor anthracycline ...

Gemtuzumab Ozogamicin - Drug Information - Chemocare

chemocare.com

Mylotarg is the trade name for gemtuzumab ozogamicin. In some cases, health care professionals may use the trade name mylotarg when referring to the ...